NEPH Stock Analysis: Buy, Sell, or Hold?
NEPH - Nephros Inc.
$4.41
0.33 (8.09%)
▲
5d:
+2.08%
30d:
+21.15%
90d:
+27.09%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When NEPH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: NEPH shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: NEPH shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$9.91
Based on 13.8% avg growth
INTRINSIC VALUE TODAY
$6.15
28.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NEPH is currently trading at $4.41, which is considered extended relative to its 30-day fair value range of $3.49 to $4.39. From a valuation perspective, the stock is trading at a discount (Forward PE: 21.0) compared to its historical average (28.8). Remarkably, the market is currently pricing in an annual earnings decline of 10.0% over the next few years. This pessimistic expectation contrasts with the company's recent 450.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, NEPH is in a strong uptrend. Immediate support is located at $3.78, while resistance sits at $4.87. The stock is showing strong short-term momentum, up 8.1% recently.
Market Sentiment: NEPH scores 31/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.25 (+41.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NEPH is in a strong uptrend. Immediate support is located at $3.78, while resistance sits at $4.87. The stock is showing strong short-term momentum, up 8.1% recently.
Market Sentiment: NEPH scores 31/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.25 (+41.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.49 -
$4.39
Company Quality Score
44/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
28.6%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (31/100)
- BULLISH: Strong upward momentum (+8.1%)
- BULLISH: Trading 41.7% below Wall St target ($6.25)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.49 -
$4.39
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.78
Resistance Level
$4.87
Current Trend
Strong Uptrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
21.00
Wall Street Target
$6.25
(+41.7%)
Revenue Growth (YoY)
36.2%
Earnings Growth (YoY)
450.0%
Profit Margin
8.4%
Valuation Discount vs History
-10.0% cheaper
PE vs Historical
21.0 vs 28.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-10.0%
(market-implied from PE analysis)
1-Year Target
$3.97
(-10%)
2-Year Target
$3.57
(-19%)
3-Year Target
$3.21
(-27%)
3-Yr Target (if PE normalizes)
(PE: 21→29)
$4.41
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.0, Growth: 23.5%)
$8.31
(+89%)
Base:
(SPY PE: 20.1, Growth: 23.5%)
$7.94
(+80%)
Bear:
(PE: 17.0, Growth: 23.5%)
$6.75
(+53%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (26x PE), but valuation improves significantly next year (21x PE) as earnings recover.
Trailing PE: 25.50 | Current EPS (TTM): $0.16
Bull Case
$5.89
(+34%)
Analyst growth 31.2%, PE expands to 28.1
Base Case
$5.35
(+21%)
Market implied 31.2%, PE stable at 25.5
Bear Case
$2.77
(-37%)
Severe decline -20.0%, PE contracts to 21.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 21.0 to 28.8
Stabilization Target:
$6.05
(+37.1%)
PE Expansion Potential:
+37.1%
Share & Embed Analysis
Last updated: August 24, 2026 9:55 PM ET
Data refreshes hourly during market hours. Next update: 10:55 PM
Data refreshes hourly during market hours. Next update: 10:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NEPH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$478 | 37 SELL |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$85 | 39 SELL |
|
WST
West Pharmaceutical Serv… |
STRONG BUY
13 analysts |
$405 | 58 HOLD |
|
RGEN
Repligen Corporation |
STRONG BUY
19 analysts |
$186 | 35 SELL |
|
RMD
ResMed Inc |
BUY
19 analysts |
$246 | 45 HOLD |
